Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
Zacks.com on MSN4d
Top Stock Reports for T-Mobile, Toyota Motor & Vertex Pharmaceuticals
Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Toyota Motor ...
Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market
This was the stock's third consecutive day of gains.
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful ...
Nasdaq2d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that ...
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results
Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $430.00 Price Target at Scotiabank
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...
Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX): ‘Their Painkiller Equaled The Placebo. And That’s Just A Shame’
We recently compiled a list of the Jim Cramer Talked About These 17 Stocks After The Fed’s Rate Cut. In this article, we are ...